Molecular BiologybioRxivPreprint
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Rupali Sharma, Bhargav Earla, Kwamena E. Baidoo…·Samira Mercedes Sadowski
This study shows that HDAC inhibitors increase SSTR2 expression in pancreatic neuroendocrine tumors, enhancing 177Lu-DOTATATE therapy efficacy in receptor-deficient models.
3 citations